Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 54: 617-619, 2008; 10.1373/clinchem.2007.095604
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vasile, V. C.
Right arrow Articles by Jaffe, A. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vasile, V. C.
Right arrow Articles by Jaffe, A. S.
(Clinical Chemistry. 2008;54:617-619.)
© 2008 American Association for Clinical Chemistry, Inc.

Letters

Relationship of MRI-Determined Infarct Size and cTnI Measurements in Patients with ST-Elevation Myocardial Infarction

Vlad C. Vasile1, Luciano Babuin1, Evangelos Giannitsis2, Hugo A. Katus2 and Allan S. Jaffe1,a

1 Departments of Internal Medicine, Division of Cardiovascular Diseases, and Laboratory Medicine and Pathology, Mayo Clinic and Mayo Medical School, Rochester, MN
2 Abteilung Innere Medizin III, Medizinische Klinik, Universitätsklinikum Heidelberg, Heidelberg, Germany

aAddress correspondence to this author at: Mayo Clinic, 200 First St SW, Division of Cardiovascular Diseases, Gonda 5, Rochester, MN 55905, Fax 507-266-0228, e-mail Jaffe.Allan@mayo.edu

The first 20% of the full text of this article appears below.


To the Editor:

The extent of myocardial infarction (MI) is related to patient outcomes (1), and clinicians often wish to have a sense for this critical measure. Imaging methods, although accurate, have limited accessibility and high cost. Thus clinicians often use biomarkers to provide such an estimate. Measurement of cardiac troponin T (cTnT) at 96 h after onset of MI was observed to correlate with MRI-determined infarct size in both ST-elevation MI (STEMI) and non-STEMI (2). We tested the hypothesis that cardiac troponin I (cTnI), another myocardium-specific biomarker, would provide an equivalent estimation in the subset of STEMI patients previously described (2).

The 28 patients with STEMI had sufficient sample remaining to allow for determination of cTnI (2). The characteristics of this group have previously been reported (2), but in brief the mean age (SD) was 56 (11) years, and 17.4% of patients were women. Mean (SD) body mass index was 26.46 (3.5) kg/m2, and 71.4% of patients were hypertensive, 64.3% . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
A. S. Jaffe
Key Issues in the Developing Synergism between Cardiovascular Imaging and Biomarkers
Clin. Chem., September 1, 2008; 54(9): 1432 - 1442.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Association for Clinical Chemistry.